Sana Biotechnology (SANA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.13
- Estimate
- -$0.12
- Surprise
- -7.9%
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Sana Biotechnology (SANA) reported a wider loss than forecast — diluted EPS of -$0.13 against the -$0.12 estimate (a 7.9% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SANA Sell at 5.2/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -7.9% surprise compares with a -0.9% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (1.6 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (17 sells, 3.94% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.86
- Price target
- $7.33
- Stop
- $3.64
- Upside to target
- +89.9%
- Reward-to-risk
- 5.8:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
SANA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.17B
- P/E (fwd)
- -7.0
- 52-week range
- $2.61–$6.55
- Off 52-week high
- 41.1%
- RSI (14)
- 67
- Volume vs avg
- 1.10×
- Score today
- 5.2/10